144 related articles for article (PubMed ID: 26933457)
21. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
Vu CC; Matthews R; Kim B; Franceschi D; Bilfinger TV; Moore WH
Nucl Med Commun; 2013 Oct; 34(10):959-63. PubMed ID: 23921784
[TBL] [Abstract][Full Text] [Related]
22. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group.
Vansteenkiste JF; Stroobants SG; Dupont PJ; De Leyn PR; Verbeken EK; Deneffe GJ; Mortelmans LA; Demedts MG
J Clin Oncol; 1999 Oct; 17(10):3201-6. PubMed ID: 10506619
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer.
Park SY; Cho A; Yu WS; Lee CY; Lee JG; Kim DJ; Chung KY
J Nucl Med; 2015 Jan; 56(1):45-9. PubMed ID: 25525185
[TBL] [Abstract][Full Text] [Related]
24. Does FDG PET/CT have a role in determining adjuvant chemotherapy in surgical margin-negative stage IA non-small cell lung cancer patients?
Park HL; Yoo IR; Boo SH; Park SY; Park JK; Sung SW; Moon SW
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1021-1026. PubMed ID: 30756189
[TBL] [Abstract][Full Text] [Related]
25. Primary tumor standardized uptake value (SUVmax) measured on
Hui Z; Wei F; Ren H; Xu W; Ren X
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2595-2605. PubMed ID: 32494919
[TBL] [Abstract][Full Text] [Related]
26. Repeat FDG-PET for predicting pathological tumor response and prognosis after neoadjuvant treatment in nonsmall cell lung cancer: comparison with computed tomography.
Shiraishi K; Nomori H; Ohba Y; Kaji M; Mori T; Shibata H; Oya N; Sasaki J
Ann Thorac Cardiovasc Surg; 2010 Dec; 16(6):394-400. PubMed ID: 21263419
[TBL] [Abstract][Full Text] [Related]
27. The role of
Lee JW; Seo KH; Kim ES; Lee SM
Eur Radiol; 2017 May; 27(5):1912-1921. PubMed ID: 27590191
[TBL] [Abstract][Full Text] [Related]
28. Prognostic stratification using F-18 FDG PET/CT in patients with advanced stage (stage III and IV) non-small cell lung cancer.
Kim YS; Lee MK; Kim SJ; Kim IJ; Kim YK; Jo WS; Park SK
Neoplasma; 2010; 57(3):241-6. PubMed ID: 20353275
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer.
Zhu D; Ma T; Niu Z; Zheng J; Han A; Zhao S; Yu J
Lung Cancer; 2011 Sep; 73(3):332-7. PubMed ID: 21292341
[TBL] [Abstract][Full Text] [Related]
30. (18)F-FDG PET/CT mean SUV and metabolic tumor volume for mean survival time in non-small cell lung cancer.
Kurtipek E; Çayci M; Düzgün N; Esme H; Terzi Y; Bakdik S; Aygün MS; Unlü Y; Burnik C; Bekci TT
Clin Nucl Med; 2015 Jun; 40(6):459-63. PubMed ID: 25742234
[TBL] [Abstract][Full Text] [Related]
31. [The prognostic impact of preoperative PET-CT on postoperative recurrence for completely resected stage I non-small cell lung cancer].
Qiang G; Xu R; Liu J; Yan J; Xu Y; Di J; Da J; Liang C; Shi B; Guo Y; Liu D
Zhonghua Wai Ke Za Zhi; 2015 Jul; 53(7):502-7. PubMed ID: 26359072
[TBL] [Abstract][Full Text] [Related]
32. Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer.
Kong FS; Li L; Wang W; Campbell J; Waller JL; Piert M; Gross M; Cheng M; Owen D; Stenmark M; Huang KC; Frey KA; Ten Haken RK; Lawrence TS
Radiother Oncol; 2019 Mar; 132():241-249. PubMed ID: 30389239
[TBL] [Abstract][Full Text] [Related]
33. [Analysis of the Role of PET/CT SUVmax in Prognosis and Its Correlation with
Clinicopathological Characteristics in Resectable Lung Squamous Cell Carcinoma].
Ren H; Xu W; You J; Song X; Huang H; Zhao N; Ren X; Zhang X
Zhongguo Fei Ai Za Zhi; 2016 Apr; 19(4):192-9. PubMed ID: 27118646
[TBL] [Abstract][Full Text] [Related]
34. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
[TBL] [Abstract][Full Text] [Related]
35. High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer.
Everitt S; Herschtal A; Callahan J; Plumridge N; Ball D; Kron T; Schneider-Kolsky M; Binns D; Hicks RJ; MacManus M
Cancer; 2010 Nov; 116(21):5030-7. PubMed ID: 20623786
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer.
Shimizu K; Okita R; Saisho S; Yukawa T; Maeda A; Nojima Y; Nakata M
Ann Nucl Med; 2015 Dec; 29(10):854-60. PubMed ID: 26254228
[TBL] [Abstract][Full Text] [Related]
37. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of tumor burden measurement using the number of tumors in non-surgical patients with non-small cell lung cancer.
Zhang H; Wroblewski K; Pu Y
Acta Radiol; 2012 Jun; 53(5):561-8. PubMed ID: 22661603
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer.
Kim K; Kim SJ; Kim IJ; Kim YS; Pak K; Kim H
Nucl Med Commun; 2012 Jun; 33(6):613-20. PubMed ID: 22407127
[TBL] [Abstract][Full Text] [Related]
40. Prognostic evaluations of small size lung cancers by 18F-FDG PET/CT and thin-section CT.
Kishimoto M; Iwano S; Ito S; Kato K; Ito R; Naganawa S
Lung Cancer; 2014 Nov; 86(2):180-4. PubMed ID: 25263854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
